Recovery Research Market

TB-500

A synthetic version of the active region of thymosin beta-4, commonly discussed for soft-tissue recovery and injury support.

RecoverySoft TissueInjuryThymosin Beta-4

Also referenced as: Thymosin Beta-4 Fragment

Also appears in: Muscle Growth

Price compare
103 tracked offers across 103 vendors · 15 dosages
Best trust-adjusted value: Southern Aminos · Moderate trust · $2.45/mg
From
$2.45/mg
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Category
Recovery

Primary lane: Recovery. Also surfaces under Muscle Growth for browsing and discovery.

Aliases
1

Thymosin Beta-4 Fragment

Signal depth
Medium

No FDA label signal · 19 trials · 736 PubMed results

Promising
Research evidence

TB-500 has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

TB-500 has 14 name-matched clinical trials (highest phase: Phase 2) and 738 PubMed-indexed publications and is not FDA-approved. 6 trials have posted results. Note: 3 retracted publications in the literature.

⚠ 3 retracted publications
Human data
Phase 2
Trial quality
Randomized
Outcomes
Clinical outcomes
Replication
Multiple trials
Literature
High-impact
PHASE2 · Randomized Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction PHASE2 · Randomized Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction PHASE1/PHASE2 · Randomized TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD Proceedings of the National Academy of Sciences · 297 citations Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Molecular Biology of the Cell · 296 citations The control of actin nucleotide exchange by thymosin beta 4 and profilin. A potential regulatory mechanism for actin polymerization in cells. Experimental Eye Research · 219 citations Thymosin Beta 4 Promotes Corneal Wound Healing and Decreases Inflammation in Vivo Following Alkali Injury
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What TB-500 is

TB-500 is a synthetic peptide associated with the active region of thymosin beta-4. It appears frequently in injury-recovery discussions, especially around connective tissue, mobility, and return-to-training conversations.

Why it matters

Alongside BPC-157, TB-500 is one of the most recognizable names in the recovery bucket. Including it makes the recovery category feel much closer to what real users expect to see.

Regulatory context

TB-500 is not an FDA-approved recovery medicine in the United States. It is best understood as a research-market compound with strong community interest and much looser regulatory footing.

Practical reading note

This is another profile where popularity can outrun evidence quality quickly, so category clarity matters more than hype.